The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism
Clinical Nephrology · 2025
DOI: 10.5414/cn111695 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Eiichi Sato und 10 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Dialysis, Calcimimetic Agents, Peptides. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Sato, E., Urata, M., Sato, S., Ono, T., Degawa, M., Lu, H., Nomura, M., Matsumura, D., Moriyama, N., Amaha, M., & Nakamura, T. (2025). The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism. Clinical Nephrology. https://doi.org/10.5414/cn111695
Vancouver
Sato E, Urata M, Sato S, Ono T, Degawa M, Lu H, et al. The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism. Clinical Nephrology. 2025. doi:10.5414/cn111695
BibTeX
@article{Sato2025,
author = {Sato, Eiichi and Urata, Miyako and Sato, Shohei and Ono, Takao and Degawa, Manaka and Lu, Hongmei and Nomura, Mayumi and Matsumura, Daisuke and Moriyama, Noriaki and Amaha, Mayuko and Nakamura, Tsukasa},
title = {The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cn111695}
}
EUVIMED